Camurus
567
SEK
+0.62 %
CAMX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
9 following
+0.62%
-1.05%
-10.07%
-1.39%
+5.39%
+8.83%
+296.5%
+568.63%
+838.34%
Camurus operates in biotechnology. The company runs as a research-based pharmaceutical company and develops and distributes products for the treatment of severe and chronic diseases. Diseases treated with the company's products include, for example, cancer, endocrine disorders, and patients with opioid dependence. Camurus runs development projects under its own auspices and in partnership with international pharmaceutical companies. The company is headquartered in Lund.
Read moreMarket cap
33.38B SEK
Turnover
18.43M SEK
Revenue
1.72B
EBIT %
30.63 %
P/E
72.88
Dividend yield-%
-
Financial calendar
13/2
2025
Annual report '24
15/5
2025
Interim report Q1'25
27/5
2025
General meeting '24
ShowingAll content types
Camurus AB: Valberedning utsedd inför Camurus årsstämma 2025
Camurus AB: Camurus presenterar vid Jefferies London Healthcare Conference
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools